Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Other
, 2025, Data from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.c.8179124
, 2025, Supplementary Fig. S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761555
, 2025, Supplementary Fig. S2 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761552
, 2025, Supplementary Fig. S3 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761549
, 2025, Supplementary Fig. S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761546
, 2025, Supplementary Fig. S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761543
, 2025, Supplementary Fig. S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761540
, 2025, Supplementary Table S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761537
, 2025, Supplementary Table S10 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761534
, 2025, Supplementary Table S11 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761531
, 2025, Supplementary Table S2 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761528
, 2025, Supplementary Table S3 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761525
, 2025, Supplementary Table S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761522
, 2025, Supplementary Table S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761519
, 2025, Supplementary Table S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761516
, 2025, Supplementary Table S7 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761513
, 2025, Supplementary Table S8 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761510
, 2025, Supplementary Table S9 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761507